Myles Minter

The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.’s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter...

Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics Analyst Brian Abrahams initiated coverage with an Outperform rating and price target of $24. Neumora...